HomeCompareANPCY vs PEP

ANPCY vs PEP: Dividend Comparison 2026

ANPCY yields 2985.07% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANPCY wins by $433539968074.97M in total portfolio value
10 years
ANPCY
ANPCY
● Live price
2985.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$433539968075.12M
Annual income
$406,736,225,519,142,500.00
Full ANPCY calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — ANPCY vs PEP

📍 ANPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANPCYPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANPCY + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANPCY pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPCY
Annual income on $10K today (after 15% tax)
$253,731.34/yr
After 10yr DRIP, annual income (after tax)
$345,725,791,691,271,200.00/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, ANPCY beats the other by $345,725,791,691,217,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPCY + PEP for your $10,000?

ANPCY: 50%PEP: 50%
100% PEP50/50100% ANPCY
Portfolio after 10yr
$216769984037.63M
Annual income
$203,368,112,759,602,980.00/yr
Blended yield
93.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

ANPCY
No analyst data
Altman Z
-11.9
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPCY buys
0
PEP buys
0
No recent congressional trades found for ANPCY or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANPCYPEP
Forward yield2985.07%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$433539968075.12M$144.7K
Annual income after 10y$406,736,225,519,142,500.00$63,430.49
Total dividends collected$431686299125.80M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ANPCY vs PEP ($10,000, DRIP)

YearANPCY PortfolioANPCY Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$309,207$298,507.46$10,854$514.44+$298.4KANPCY
2$8,957,089$8,626,236.93$11,982$758.21+$8.95MANPCY
3$243,120,454$233,536,368.64$13,526$1,136.44+$243.11MANPCY
4$6,184,279,490$5,924,140,604.30$15,727$1,741.93+$6184.26MANPCY
5$147,451,722,719$140,834,543,664.57$19,012$2,750.28+$147451.70MANPCY
6$3,296,013,356,428$3,138,240,013,119.13$24,173$4,514.44+$3296013.33MANPCY
7$69,087,118,460,072$65,560,384,168,694.19$32,789$7,793.80+$69087118.43MANPCY
8$1,358,221,282,082,432$1,284,298,065,330,154.50$48,258$14,354.51+$1358221282.03MANPCY
9$25,050,226,687,827,436$23,596,929,915,999,230.00$78,586$28,686.63+$25050226687.75MANPCY
10$433,539,968,075,117,900$406,736,225,519,142,500.00$144,688$63,430.49+$433539968074.97MANPCY

ANPCY vs PEP: Complete Analysis 2026

ANPCYStock

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Full ANPCY Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this ANPCY vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPCY vs SCHDANPCY vs JEPIANPCY vs OANPCY vs KOANPCY vs MAINANPCY vs MOANPCY vs PMANPCY vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.